Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Slides:

Advertisements

Similar presentations

Giuseppe Biondi-Zoccai Division of Cardiology, University of Turin, Turin, Italy.

Advertisements

Safety of Cyclooxygenase-2 (COX-2) inhibitors, Valdecoxib and Parecoxib, versus Placebo for Post CABG Pain Management Presented at American College of.

¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

Canadian Cardiovascular Society Antiplatelet Guidelines

Learning Objectives. Learning Objectives Variable Response to Clopidogrel.

Preventing Thrombotic Complications in ACS: State of the Art

Oral Anticoagulation and Preventing Stent Thrombosis

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

New Concepts in Peripheral Artery Disease: Emerging Role of Antithrombotics.

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

The Role of Anticholinergic Therapy in Moderate to Severe Asthma

Glenn N. Levine et al. JACC 2016;68:

Diabetes and Dyslipidemia

US Guidelines US Guidelines Low-risk Patients.

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Applying New Data in Practice:

PAD Patients vs Post-ACS Patients:

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Glenn N. Levine et al. JACC 2016;68:

Unmet Needs in the Secondary Prevention in ACS

Introduction Antiplatelet Agents ADP Receptor Antagonists.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

What Has Been Tried and What Is True?

Selecting NOACs for High-Risk Patients

Tailoring Antiplatelet Therapy in PCI

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Antiplatelet Therapy and Secondary Prevention

CDK4/6 Inhibitors in Practice

An Update on PCSK9 Inhibitors

NOACS: Emerging data in ACS/IHD

AF and PCI in Practice.

PCSK9 Inhibitors and Cardiovascular Outcomes

Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.

A Better Solution For Cancer Patients With VTE?

Reversal Strategies for VKA: Truths and Misconceptions

Thank you for taking the pre-assessment

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

Mitral Valve Disease.

2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease Glenn N. Levine, MD, FACC, FAHA,

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Aspirin and Cardioprevention in 2018

Identifying High-Risk AF Patients

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Duration of Dual Antiplatelet Therapy

Factor Xa Inhibitors in PAD

A Time for Change for Managing Patients With VTE Who Have Cancer

CAD and HF Often Coexist

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

What oral antiplatelet therapy would you choose?

Reducing Risk for CV Outcomes

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Factor Xa Inhibitors in Coronary Artery Disease

Cardiology Fellow X Factor: An ACS Case of Therapeutic Challenges

Roberta Rossini et al. JCIN 2018;11:

An Update on PCSK9 Inhibitors

ESC Guideline on the Management of STEMI Recommendation for DAPT

What's New in Oral Combination Therapy for Type 2 Diabetes?

American College of Cardiology/American Heart Association 2016 dual antiplatelet therapy (DAPT) focused update: Implications for surgeons Richard J.

PCSK9 Inhibitors and Real-World Evidence

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Translating Data From Trial to Practice

Presentation transcript:

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical Patient

The educational objectives of this program are to:

Question 1

Answer

Question 2

Answer

Aspirin Resistance

Different Antiplatelet Class

P2Y12 Inhibitors Pre-CABG

P2Y12 Inhibitors Post-CABG

Registries

Clopidogrel vs Other P2Y12 Inhibitors

Primary and Secondary Efficacy Endpoints From Time of CABG

Safety: Bleeding Post-CABG

Safety: Bleeding Post-CABG Cont

2011 Update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines

Valvular Heart Disease

Remaining Questions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)